Please assess the completion status of the following clinical trial:

Trial Title: A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
ENTRY CRITERIA:~DISEASE CHARATERISTICS:~* Histologically confirmed high-risk (high grade Ta, T1 or carcinoma in situ, tumor \>4 cm or multi-focal) transitional cell carcinoma s/p TURBT with no remaining resectable disease within 4 weeks of study entry~* Intolerant of treatment with BCG or failure (refractory or relapsing) of at least one prior treatment with BCG~* Refuse or intolerant of a radical cystectomy~* No Evidence of regional and/or distant metastasis~PRIOR/CONCURRENT THERAPY:~* No concurrent radiotherapy, other chemotherapy, or other immunotherapy~* No scheduled radiotherapy, chemotherapy, other immunotherapy, or surgery before the scheduled response evaluation~* Must have recovered from side effects of prior treatments~* No concurrent use of other investigational agents~PATIENT CHARACTERISTICS:~Age~• ≥ 18 years~Performance Status~• ECOG 0, 1, or 2~Bone Marrow Reserve~* Absolute neutrophil count (AGC/ANC) ≥ 1,000/uL~* Platelets ≥ 100,000/uL~* Hemoglobin ≥ 8 g/dL~Renal Function~• Glomerular Filtration Rate (GFR) ≥ 50mL/min~Hepatic Function~* Total bilirubin ≤ 2.0 X ULN~* AST, ALT, ALP ≤ 3.0 X ULN~Cardiovascular~* No congestive heart failure \< 6 months~* No severe/unstable angina pectoris \< 6 months~* No myocardial infarction \< 6 months~* No history of ventricular arrhythmias~* No NYHA Class \> II CHF~* No uncontrollable supraventricular arrhythmias~* No history of a ventricular arrhythmia~* No other clinical signs of severe cardiac dysfunction~* Normal Transthoracic Echocardiogram (TTE) is required for patients who have history of EKG abnormalities, CHF, coronary artery disease or other cardiac disease, or have history of having received adriamycin or doxorubicin~* No patients with a left ventricular ejection fraction (LVEF) of less than 50%~Pulmonary~• Normal clinical assessment of pulmonary function~Other~* Negative serum pregnancy test if female and of childbearing potential~* Women who are not pregnant or nursing~* Subjects, both females and males, with reproductive potential must agree to use effective contraceptive measures for the duration of the study~* No known autoimmune disease other than corrected hypothyroidism~* No known prior organ allograft or allogeneic transplantation~* Not HIV positive~* No active systemic infection requiring parenteral antibiotic therapy~* No ongoing systemic steroid therapy required~* No history or evidence of uncontrollable CNS disease~* No psychiatric illness/social situation~* No other illness that in the opinion of the investigator would exclude the subject from participating in the study~* Must provide informed consent and HIPAA authorization and agree to comply with all protocol-specified procedures and follow-up evaluations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 0.06 mg/kg ALT-801 with 1000 mg/m^2 Gemcitabine (Type: EXPERIMENTAL): ALT-801 at 0.06 mg/kg with Gemcitabine at 1000 mg/m\^2
- 0.08 mg/kg ALT-801 with 1000 mg/m^2 Gemcitabine (Type: EXPERIMENTAL): ALT-801 at 0.08 mg/kg with Gemcitabine at 1000 mg/m\^2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues